Anal

Tavanta Therapeutics to Showcase Specialty Pipeline During the 2023 American Society of Clinical Oncology (ASCO) and American Society of Colon and Rectal Surgeons (ASCRS) Annual Congresses

Retrieved on: 
Wednesday, May 31, 2023
Dysphagia, Pharmacy, Metastasis, Abiraterone acetate, PDT, ASCRS, American Society of Colon and Rectal Surgeons, ASCO, American Society of Clinical Oncology, Anal, Patient, Alternative, Annual general meeting, Anal fissure, Poster, CDT, FDA, Therapy, Society, Potential, Pharmaceutical industry

"At ASCRS, we are excited to present the first data from our Phase 2 study of TAVT-119 in people with anal fissure.

Key Points: 
  • "At ASCRS, we are excited to present the first data from our Phase 2 study of TAVT-119 in people with anal fissure.
  • Currently, non-surgical options to treat anal fissures include topical nitrates (which are limited by headache/tolerability) and topical calcium channel blockers (which are only available via compounding pharmacies as none are FDA-approved for anal fissure).
  • Based on the data that will be presented, we believe that TAVT-119 has the potential to offer patients a therapeutic option that is safe, efficacious and accessible."
  • "We are pleased to highlight these promising new data, which reflect the significant progress of our clinical development programs," said Lynne Powell, Chief Executive Officer of Tavanta Therapeutics.

Emmes Supports Groundbreaking Anal Cancer Study Sponsored by the National Cancer Institute

Retrieved on: 
Thursday, June 16, 2022
Industry, Public health, The New England Journal of Medicine, HIV/AIDS, Fortis Healthcare, Anal cancer, Risk, National Cancer Institute, Woman, Man, Cancer, Research, Subclinical infection, Adoption, UCSF, Biotechnology, USCF, Disease, Vaccination, MD, University, Health, Quality of life, AMC, HIV, History, Preventive healthcare, Incidence, Standard of care, Infection, Patient, University of California, San Francisco, Federation, Multimedia, Conference, Vulvar cancer, HSIL, HPV, Conference on Retroviruses and Opportunistic Infections, CRO, Anal, Pharmaceutical industry, Medicine, EMMS International

ROCKVILLE, Md., June 16, 2022 /PRNewswire/ -- Emmes, a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that a team of its researchers contributed to a successful AIDS Malignancy Consortium (AMC) study. Results of the study, which demonstrated that treating and removing anal cancer precursor lesions reduced the cancer risk for HIV-infected men and women, were published in the New England Journal of Medicine. The Phase 3 trial results included 4,446 participants at 21 clinical sites across the U.S. and Puerto Rico.

Key Points: 
  • Results of the study , which demonstrated that treating and removing anal cancer precursor lesions reduced the cancer risk for HIV-infected men and women, were published in the New England Journal of Medicine.
  • The study enrolled people living with HIV aged 35 years and older who had at least one precursor lesion for anal cancer, called high-grade squamous intraepithelial lesions (HSIL).
  • According to Dr. Palefsky, "Anal cancer is the fourth most common cancer among people living with HIV.
  • For these individuals, the ANCHOR study shows for the first time that secondary prevention of anal cancer is possible through treatment of anal HSIL.

NICE Recommends Bioprosthetic Plug for Anal Fistulas

Retrieved on: 
Monday, September 30, 2019
MEN, Other Health, General Health, Consumer, Medical devices, Hospitals, Surgery, Biotechnology, Health, Medicine, Colorectal surgery, Anal fistula, Fistulas, Anal, Plug

The National Institute for Health and Care Excellence (NICE) Interventional Procedures Advisory Committee in the UK has recommended bioprosthetic fistula plugs as a treatment option for anal fistulas.

Key Points: 
  • The National Institute for Health and Care Excellence (NICE) Interventional Procedures Advisory Committee in the UK has recommended bioprosthetic fistula plugs as a treatment option for anal fistulas.
  • View the full release here: https://www.businesswire.com/news/home/20190929005025/en/
    Cook Medicals unique Biodesign Anal Fistula Plug Set (Graphic: Business Wire)
    In a statement, NICE said, Current evidence on the safety and efficacy of bioprosthetic plug insertion for anal fistula is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit.
  • Cook Medical, the market leader for bioprosthetic anal fistula plugs in Europe, recognises this as a positive announcement for patients.
  • Cooks unique Biodesign Anal Fistula Plug Set is designed to help heal anal fistulas without cutting into the sphincter muscles.

Global Anal Fissure Market and Competitive Landscape Report 2018

Retrieved on: 
Friday, November 2, 2018
Health, Anal fissure, RTT, Fissure, Anal, Tooth decay, Clinical trial

The "Global Anal Fissure Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anal Fissure Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • The latest research Global Anal Fissure Market and Competitive Landscape - 2018, provides comprehensive insights into Anal Fissure pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • The research is classified into following sections - Anal Fissure overview with definitions, symptoms, etiology, diagnosis, treatment options; Anal Fissure pipeline insights covering late stage clinical trials pipeline; Anal Fissure prevalence trends by countries; Anal Fissure market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.
  • Anal Fissure pipeline: Find out the drugs in clinical trials for Anal Fissure by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
    Anal Fissure epidemiology: Find out the prevalence of Anal Fissure by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; prevalence forecast to 2023
    Anal Fissure products: Identify key products marketed and prescribed for Anal Fissure by brand name, by molecule, by company, by branded / generic, by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Anal Fissure market size: Find out the market size for Anal Fissure drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; Find out how the market advanced from 2014
    Anal Fissure drug sales: Find out the sales of Anal Fissure drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan, Global
    Anal Fissure drugs sales forecast: Sales forecast for Anal Fissure drugs to 2023 by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Anal Fissure market share analysis: Find out the market shares of Anal Fissure drugs and outlook by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Did you know that we also offer Custom Research?